ARTICLE | Clinical News
ISV-403: Phase I
February 17, 2003 8:00 AM UTC
ISV filed an IND to start Phase I trials of ISV-403 in the second quarter of 2003. As a result of the filing, ISV will receive an equity investment from BOL, which has exclusive rights to ISV-403 worl...